The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum Corp. (SOLV) reported third-quarter 2026 net sales of $1.949 billion, down 7.0% from $2.096 billion a year earlier, and a $12 million net loss versus $1.266 billion net income. Operating income was $68 million, compared with $1.690 billion; 2025 included a $1.518 billion gain on the Purification and Filtration sale. Solventum said customers reduced inventories to normal levels after advance orders ahead of its July 2026 enterprise resource planning deployment.
For the first nine months, operating cash flow was $215 million. The company repurchased 5.3 million shares for $403 million under a program authorizing purchases up to $1 billion. Solventum intends to pursue a separation of Health Information Systems and is evaluating pathways. Its four-year Transform for the Future program is expected to generate approximately $500 million in annual savings once fully implemented, with approximately $500 million in total pretax costs.
Solventum Corp. reported third-quarter 2026 sales of $1.949 billion, down 7.0% reported and 2.8% organically. It recorded a GAAP net loss of $12 million, versus net income of $1.266 billion a year earlier; the 2025 quarter included a $1.518 billion gain on sale of its Purification and Filtration business. Adjusted diluted EPS was $1.45, down 3.6%. Operating cash flow was $177 million, compared with $75 million, and free cash flow was $97 million versus negative $22 million. Solventum attributed the organic sales decline to an expected 630-basis-point reversal of advance orders placed before the ERP system cutover.
For full-year 2026, Solventum expects organic sales growth toward the high end of +2.5% to +3.0% and raised adjusted EPS guidance to $7.20 to $7.30 from $7.10 to $7.20; it affirmed free cash flow guidance of $200 million to $300 million. The company said ERP system cutovers are complete and about 90% of 3M transition service agreements have been exited. It also received FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy.
Solventum Corp (SOLV) reported that Chief Executive Officer and director Bryan C. Hanson settled 67,261 Restricted Stock Units into an equal number of shares of Common Stock on September 1, 2026. As part of the same event, 26,468 shares of Common Stock were delivered or withheld to cover the exercise price or tax liability at $90.95 per share, with the remaining shares retained as directly owned Common Stock. The RSUs used in this transaction were fully vested and, after settlement, no units from this grant remained outstanding.
Solventum Corp (symbol: SOLV) is the issuer of record for a Form 4 filing submitted to the SEC.
Solventum Corp (ticker SOLV) reported the initial insider ownership status of Neil Craig Zieselman, who serves as SVP, Controller & CAO. The Form 3 shows no reported transactions or equity holdings for this officer at the time of filing. A Power of Attorney is referenced, authorizing filing-related actions.
Solventum Corporation reported mixed results for the quarter ended June 30, 2026. Total net sales were $2,209 million, up from $2,161 million a year earlier, with organic sales growth of 9.5% driven by MedSurg and Dental Solutions and aided by about $125 million of advanced customer orders ahead of a July 2026 ERP deployment, which is expected to pressure third-quarter sales.
Quarterly net income was $92 million and diluted earnings per share were $0.53, little changed from the prior year, while operating income declined to $181 million as higher selling, general and administrative costs offset margin gains from lower cost of product. Results included a $100 million pre-tax benefit from IEEPA tariff refunds recorded in cost of product and $204 million of legal charges, mainly related to product litigation, which increased accrued litigation costs to $235 million.
For the first six months of 2026, net sales were $4,216 million versus $4,231 million and net income fell to $105 million from $227 million, reflecting the absence of a prior-year tax benefit, restructuring and legal costs. Operating cash flow was $38 million, while the company repurchased $355 million of stock and ended June with $403 million in cash and $5,079 million of total debt. Management is executing its four-year “Transform for the Future” program, targeting about $500 million in annual cost savings for roughly $500 million in cumulative pretax costs, and has announced plans to pursue a separation of the Health Information Systems business.
Solventum Corporation reported second-quarter 2026 net sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. GAAP diluted EPS was $0.53, while adjusted diluted EPS was $2.55, a 50.9% increase, as adjusted operating margin expanded to 28.4% from 21.9%.
Operating cash flow reached $227 million and free cash flow was $144 million, helped by timing of tax payments and insurance proceeds. Year-to-date, GAAP net income was $105 million versus $227 million a year earlier, though adjusted diluted EPS rose to 4.02 from 3.03.
The company announced plans to separate its Health Information Systems segment to sharpen its MedTech focus and raised full-year 2026 guidance, now expecting organic sales growth of 2.5%–3.0%, adjusted EPS of $7.10–$7.20, and free cash flow of $200–$300 million.
Solventum Corporation announced its intention to pursue a separation of its Health Information Systems business as part of a broader portfolio optimization and three‑phase transformation strategy. The goal is to create a more focused MedTech company centered on MedSurg and Dental Solutions while positioning Health Information Systems for independent growth.
Health Information Systems is described as a leading healthcare software business generating $1.4 billion in net sales for the twelve months ended December 31, 2025. Its solutions are deployed in 30+ countries, used by more than 75% of U.S. hospitals, and process approximately 660 million clinical documents monthly. The business operates in a roughly $10 billion addressable market estimated to be growing 5–6% annually, with a differentiated offering in revenue cycle and performance management, clinician productivity, and AI‑driven autonomous coding.
Solventum is evaluating a range of separation alternatives, including forming an independent company, combining with a larger player, or other structures, with a targeted completion window of 12 to 18 months. The company notes there is no assurance a separation will occur and that any transaction would require Board and regulatory approvals. Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC are financial advisors, and Cleary Gottlieb Steen & Hamilton LLP is legal counsel.
Solventum Corporation appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026. He will report to Chief Financial Officer Wayde McMillan, serve as the company’s Principal Accounting Officer for SEC reporting, and replace Mary Wilcox following her previously announced retirement.
Zieselman, age 50, joins from Surgery Partners, Inc., where he was Senior Vice President, Corporate Finance and Controller. His prior roles include senior finance leadership positions at Stryker Corporation, Covanta Holding Corporation, Cendant Corporation and Avaya Inc. He began his career at PricewaterhouseCoopers, is a licensed CPA, and graduated summa cum laude from Rider University.
His compensation includes an annual base salary aligned with role scope and experience, a target annual bonus of 50% of base salary, eligibility for an annual long-term incentive target award of $500,000, a cash sign-on bonus of $130,000, and an initial grant of $600,000 in restricted stock units vesting in three equal installments, plus participation in the Solventum Executive Severance Plan.
Solventum Corporation reports the resolution of a Delaware Court of Chancery class action that challenged certain advance notice and stockholder nomination provisions in its By-laws. The company had already amended the challenged By-law provisions on September 20, 2024.
Following the amendment, the plaintiff moved to dismiss the case as moot but sought attorneys’ fees and expenses. After arm’s-length negotiations, Solventum agreed to pay $120,000 to the plaintiff’s counsel in full satisfaction of all fee and expense claims related to the By-laws amendment. On June 2, 2026, the Court entered an order closing the case and directing that notice of the agreed fee payment be provided through this report, without reviewing or passing judgment on the amount or reasonableness of the fees.